Jialin Wang

Dr. Jialin Wang


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2020 in Cancer
Verified
Journal Article
Closed access
PDF file
NZNan Zhang
Nan Zhang
YLYanyan Li
Yanyan Li
XCXuan Chang
Xuan Chang
FLFuhua Lei
Fuhua Lei
HMHengmin Ma
Hengmin Ma
JWJialin Wang
Jialin Wang

19 August 2022 in Health and Quality of Life Outcomes
Verified
Journal Article
Open access
PDF file
MSMingzhu Su
Mingzhu Su
NYNengliang Yao
Nengliang Yao
MSMeimei Shang
Meimei Shang
YSYuzhen Shen
Yuzhen Shen
TQTingting Qin
Tingting Qin
XSXiaojie Sun
Xiaojie Sun
Background: There is limited information about the population characteristics and adverse health outcomes of older cancer patients in China. This study aimed to describe the prevalence of frailty and examine the association between frailty and health-related quality of life (HRQoL) among older cancer patients. Methods: This was a cross-sectional study involving older patients diagnosed with cancer in two tertiary hospitals in Shandong Province, China. Frailty was assessed using Geriatric 8 (G-8). HRQoL was measured using the five-level EuroQol-5-dimension (EQ-5D-5L) questionnaire. The Tobit regression model and logistic regression model was used to identify the relationship between frailty and HRQoL. Results: Of the 229 older patients, 175 (76.4%) were frail. Frail patients had lower EQ-5D-5L utility scores than those who were non-frail (0.830 vs. 0.889; P = 0.004). After adjustments for sociodemographic and cancer-related variables, frailty was statistically associated with worse health-related quality of life (OR = 6.024; P = 0.001). Conclusion: Frailty was associated with deteriorated HRQoL in older patients with cancer. Early frailty screening and preventive interventions are essential for improving quality of life through decision-making or pretreatment optimization in geriatric oncology.

3 January 2023 in JAMA Network Open
Verified
Journal Article
Closed access
PDF file
JHJunming Han
Junming Han
XGXiaolei Guo
Xiaolei Guo
LZLi Zhao
Li Zhao
HZHuan Zhang
Huan Zhang
SMSiqi Ma
Siqi Ma
FXFuzhong Xue
Fuzhong Xue
Globally, esophageal cancer ranks eighth among common malignant tumors and sixth among cancer-related causes of death.1-3 In China, the number of new cases of esophageal cancer in 2020 was 324 422 (95% uncertainty interval, 319 432-329 490), while the age-standardized rate was 13.8 per 100 000 population, ranking sixth among common malignant tumors.4-6 Esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC) are 2 main histological subtypes of esophageal cancer. Esophageal adenocarcinoma is more common in Western countries with a rising incidence,7 while ESCC accounts for over 90% of esophageal cancer cases and is more common in East Africa, Central Asia, and China. Although the incidence of ESCC declined slightly, it is still high.5,8,9

30 June 2022 in Cancer Medicine
Verified
Journal Article
Open access
DGDongqing Gao
Dongqing Gao
PLPeipei Lu
Peipei Lu
NZNan Zhang
Nan Zhang
LZLi Zhao
Li Zhao
JLJinhui Liu
Jinhui Liu
JWJialin Wang
Jialin Wang
Background and aims: This study investigated the natural history of esophageal squamous cell carcinoma (ESCC) in rural Chinese. We sought to help provide more data to support ESCC screenings.Methods: This study was based on an existing Screening Program in Feicheng, China. Esophageal precancerous lesions were identified in 1753 cases, diagnosed from esophageal cancer screenings from 2006 to 2016. We followed up with them through endoscopic screening until October 1, 2017. Pathology results from various grades of precancerous lesions were recorded and the annual transition probabilities and incidence density of ESCC were calculated.Results: As of October 1, 2017, a total of 4055.8 person‐years has been observed. The ESCC incidence density of mild, moderate, and severe dysplasia (SD) was 0.17, 0.79, and 1.77 per 100 person‐years, respectively. The median follow‐up time of mild, moderate, and SD was 3.5, 2.3, and 2.2 years, respectively. The annual transition probability of mild, moderate, and SD to the next pathological level was 0.025, 0.038, and 0.016, respectively. The ESCC incidence density of males was 2.6 times higher than females (0.58 vs. 0.22), and the older age group (56–69 age group) had a ESCC incidence density 1.2 times higher than the younger group (40–55 age group) (0.45 vs. 0.39).Conclusions: The higher the grade of precancerous lesions, the higher the incidence density of ESCC. Screening of esophageal cancer in males and the elderly should be strengthened. It is recommended to reinforce follow‐up management for untreated patients with SD/carcinoma in situ. For patients with mild and moderate dysplasia in high‐risk rural Chinese populations, endoscopic follow‐up intervals can be appropriately adjusted to once every 2 years.

14 March 2024 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
YSYawen Sun
Yawen Sun
WLWenjuan Liu
Wenjuan Liu
MSMu Su
Mu Su
TZTao Zhang
Tao Zhang
XLXia Li
Xia Li
JYJinming Yu
Jinming Yu
Esophageal squamous cell carcinoma (ESCC) remains an important health concern in developing countries. Patients with advanced ESCC have a poor prognosis and survival rate, and achieving early diagnosis remains a challenge. Metabolic biomarkers are gradually gaining attention as early diagnostic biomarkers. Hence, this multicenter study comprehensively evaluated metabolism dysregulation in ESCC through an integrated research strategy to identify key metabolite biomarkers of ESCC. First, the metabolic profiles were examined in tissue and serum samples from the discovery cohort (n = 162; ESCC patients, n = 81; healthy volunteers, n = 81), and ESCC tissue-induced metabolite alterations were observed in the serum. Afterward, RNA sequencing of tissue samples (n = 46) was performed, followed by an integrated analysis of metabolomics and transcriptomics. The potential biomarkers for ESCC were further identified by censoring gene-metabolite regulatory networks. The diagnostic value of the identified biomarkers was validated in a validation cohort (n = 220), and the biological function was verified. A total of 457 dysregulated metabolites were identified in the serum, of which 36 were induced by tumor tissues. The integrated analyses revealed significant alterations in the purine salvage pathway, wherein the abundance of hypoxanthine/xanthine exhibited a positive correlation with HPRT1 expression and tumor size. A diagnostic model was developed using two purine salvage–associated metabolites. This model could accurately discriminate patients with ESCC from normal individuals, with an area under the curve (AUC) (95% confidence interval (CI): 0.680–0.843) of 0.765 in the external cohort. Hypoxanthine and HPRT1 exerted a synergistic effect in terms of promoting ESCC progression. These findings are anticipated to provide valuable support in developing novel diagnostic approaches for early ESCC and enhance our comprehension of the metabolic mechanisms underlying this disease.

1 December 2023 in BMC Cancer
Verified
Journal Article
Open access
PDF file
ZSZiqian Song
Ziqian Song
HMHengmin Ma
Hengmin Ma
HSHao Sun
Hao Sun
QLQiuxia Li
Qiuxia Li
YLYan Liu
Yan Liu
JWJialin Wang
Jialin Wang
Background: Patients diagnosed with small cell lung cancer (SCLC) typically experience a poor prognosis, and it is essential to predict overall survival (OS) and stratify patients based on distinct prognostic risks. Methods: Totally 2309 SCLC patients from the hospitals in 15 cities of Shandong from 2010 − 2014 were included in this multicenter, population-based retrospective study. The data of SCLC patients during 2010–2013 and in 2014 SCLC were used for model development and validation, respectively. OS served as the primary outcome. Univariate and multivariate Cox regression were applied to identify the independent prognostic factors of SCLC, and a prognostic model was developed based on these factors. The discrimination and calibration of this model were assessed by the time-dependent C-index, time-dependent receiver operator characteristic curves (ROC), and calibration curves. Additionally, Decision Curve Analysis (DCA) curves, Net Reclassification Improvement (NRI), and Integrated Discriminant Improvement (IDI) were used to assess the enhanced clinical utility and predictive accuracy of the model compared to TNM staging systems. Results: Multivariate analysis showed that region (Southern/Eastern, hazard ratio [HR] = 1.305 [1.046 − 1.629]; Western/Eastern, HR = 0.727 [0.617 − 0.856]; Northern/Eastern, HR = 0.927 [0.800 − 1.074]), sex (female/male, HR = 0.838 [0.737 − 0.952]), age (46–60/≤45, HR = 1.401 [1.104 − 1.778]; 61–75/≤45, HR = 1.500 [1.182 − 1.902]; >75/≤45, HR = 1.869 [1.382 − 2.523]), TNM stage (II/I, HR = 1.119[0.800 − 1.565]; III/I, HR = 1.478 [1.100 − 1.985]; IV/I, HR = 1.986 [1.477 − 2.670], surgery (yes/no, HR = 0.677 [0.521 − 0.881]), chemotherapy (yes/no, HR = 0.708 [0.616 − 0.813]), and radiotherapy (yes/no, HR = 0.802 [0.702 − 0.917]) were independent prognostic factors of SCLC patients and were included in the nomogram. The time-dependent AUCs of this model in the training set were 0.699, 0.683, and 0.683 for predicting 1-, 3-, and 5-year OS, and 0.698, 0.698, and 0.639 in the validation set, respectively. The predicted calibration curves aligned with the ideal curves, and the DCA curves, the IDI, and the NRI collectively demonstrated that the prognostic model had a superior net benefit than the TNM staging system. Conclusion: The nomogram using SCLC patients in Shandong surpassed the TNM staging system in survival prediction accuracy and enabled the stratification of patients with distinct prognostic risks based on nomogram scores.